Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (271-280 of 491) with videos related to

Pageof 50
Sort By:
The Lancet. Oncology|July 23, 2013
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studySant Chawla, Robert Henshaw, Leanne Seeger, et al.
Postepy Dermatologii I Alergologii|December 17, 2019
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre studyBożena Cybulska-Stopa, Iwona Ługowska, Paulina Jagodzińska-Mucha, et al.
Annals of Surgical Oncology|May 29, 2014
Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary siteAleksandra Gos, Monika Jurkowska, Alexander van Akkooi, et al.
The Lancet. Oncology|November 10, 2019
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 studySant Chawla, Jean-Yves Blay, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsPiotr Rutkowski, Martine Van Glabbeke, Cathryn J Rankin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 23, 2020
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practicePiotr Rutkowski, Marcin Ziętek, Bożena Cybulska-Stopa, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 31, 2007
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumorsPiotr Rutkowski, Maria Debiec-Rychter, Zbigniew I Nowecki, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 19, 2024
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr Błoński, et al.
Melanoma Research|November 9, 2020
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patientsBożena Cybulska-Stopa, Marcin Ziętek, Grażyna Kamińska-Winciorek, et al.
Targeted Oncology|June 24, 2025
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SDAnna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, et al.
Pageof 50

Showing results (271-280 of 491) with videos related to

Sort By:
Pageof 50
The Lancet. Oncology|July 23, 2013
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studySant Chawla, Robert Henshaw, Leanne Seeger, et al.
Postepy Dermatologii I Alergologii|December 17, 2019
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre studyBożena Cybulska-Stopa, Iwona Ługowska, Paulina Jagodzińska-Mucha, et al.
Annals of Surgical Oncology|May 29, 2014
Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary siteAleksandra Gos, Monika Jurkowska, Alexander van Akkooi, et al.
The Lancet. Oncology|November 10, 2019
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 studySant Chawla, Jean-Yves Blay, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsPiotr Rutkowski, Martine Van Glabbeke, Cathryn J Rankin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 23, 2020
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practicePiotr Rutkowski, Marcin Ziętek, Bożena Cybulska-Stopa, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 31, 2007
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumorsPiotr Rutkowski, Maria Debiec-Rychter, Zbigniew I Nowecki, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 19, 2024
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr Błoński, et al.
Melanoma Research|November 9, 2020
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patientsBożena Cybulska-Stopa, Marcin Ziętek, Grażyna Kamińska-Winciorek, et al.
Targeted Oncology|June 24, 2025
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SDAnna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, et al.
Pageof 50